Journals / Nöropsikiyatri Arşivi / 2014 / Cilt: 51 - Sayı: 1

Nörolojik hastalıklarda terapötik plazma değişimi: 91 hasta ile yedi yıllık deneyim sonuçları

Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***

Pages
63–68
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conc­lu­si­on: The improvement rates were encouraging and we concluded that significant benefit can be achieved with TPE for the treatment of neuroimmunological disorders.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, we report the results of our experience of therapeutic plasma exchange (TPE) for neuroimmunologic disorders performed at our hospital over a seven-year period.
📊
Key Findings & Data:Met­hods: We retrospectively reviewed the medical records of 91 patients (53 male, 38 female) who had been treated at our center with TPE.
💡
Conclusion & Impact:Conc­lu­si­on: The improvement rates were encouraging and we concluded that significant benefit can be achieved with TPE for the treatment of neuroimmunological disorders.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: In this study, we report the results of our experience of therapeutic plasma exchange (TPE) for neuroimmunologic disorders performed at our hospital over a seven-year period. Met­hods: We retrospectively reviewed the medical records of 91 patients (53 male, 38 female) who had been treated at our center with TPE. Re­sults: 60 patients with Guillain-Barrè syndrome (GBS), 23 with myasthenia gravis (MG), 4 with chronic inflammatory demyelinating polyneuropathy (CIDP) and 1 patient each with polymyositis, septic encephalopathy, acute disseminated encephalomyelitis (ADEM) and Opsoclonus-Myoclonus syndrome (OMS) received TPE. 26.7% of GBS patient’s made complete recovery, 61.7% had partial recovery and 11.7% patients died due to respiratory failure. Despite our best efforts and effective TPE treatments, 13.4% of MG patients deceased, however, 78% had full recovery. Three patients with CIDP were discharged with full and 1 patient with partial recovery. The patient with ADEM had partial recovery with TPE at first, but deceased 2 months later due to pneumonia-related respiratory insufficiency. While, patient with polymyositis had slight-partial recovery, we obtained full recovery with TPE in septic encephalopathy and OMS patients. The side effects and complications of treatments with TPE, which included hypotension, hypocalcaemia and anemia, were mild and manageable. Conc­lu­si­on: The improvement rates were encouraging and we concluded that significant benefit can be achieved with TPE for the treatment of neuroimmunological disorders.

Özet

Giriş: Bu çalışmada, terapötik plazma değişimi (TPD) ile tedavi ettiğimiz nöro- immünolojik olgulara ait 7 yıllık deneyimimizin sonuçları rapor edilmiştir. Yön­tem­: TPD uyguladığımız 91 olgunun (53 erkek, 38 kadın) medikal kayıtları geriye dönük olarak incelenmiştir. Bul­gu­lar: Tanısal olarak sınıflandığında, bu olguların 60’ının Guillain- Barre sendromu (GBS), 23’ünün Miyastenia Gravis (MG), 4’ünün ise kronik inflammatuar demiyelinizan polinöropati (KİDP) tanısıyla TPD aldığı görülmüştür. Birer olguya ise, polimiyozit, septik ensefalopati, akut dissemine ensefalomiyelit (ADEM) ve Opsoklonus-Myoklonus sendromu (OMS) tanılarıyla TPD uygulanmıştır. GBS hastalarımızın %26,7’sinde tam düzelme, %61,7’sinde kısmi düzelme izlenmiş olup, disabilitesi yüksek %11,7 hasta solunum yetmezliği nedeniyle kaybedilmiştir. MG’li hastaların %13,4’ünde tedaviye rağmen ölüm, %78’inde tam klinik düzelme gözlenmiştir. KIDP’li 4 hastamızın üçünde total, birinde kısmi düzelme gözlenmiş, ADEM’li olgumuz TPD ile önce kısmen düzelmiş ancak tedaviden 2 ay sonra aspirasyon pnömonisine bağlı solunum yetmezliği nedeniyle kaybedilmiş, polimiyozitli olgumuzda kısmi, septik ensefalopati ve OMS’li hastalarımızda tam düzelme gözlenmiştir. TPE uygulamasında karşılaştığımız yan etkiler hipotansiyon, hipokalsemi ve anemi gibi hafif ve yönetilebilir düzeydedir. So­nuç: Çalışmamızın sonuçları otoimmün kökenli nörolojik hastalıklarda TPE tedavisinin etkili ve güvenilir bir yöntem olduğunu göstermektedir.

🔖

Cite This Article

KARACA, S., KOZANOĞLU, İ., KARAKURUM, B. G., KARATAŞ, M., TAN, M., YERDELEN, V. D., GİRAY, S., ARLIER, Z. (2014). Nörolojik hastalıklarda terapötik plazma değişimi: 91 hasta ile yedi yıllık deneyim sonuçları. Nöropsikiyatri Arşivi, Cilt: 51 - Sayı: 1, 63–68. https://ajindex.com/articles/292536

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hughes RAC, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn P. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130:2245-2257
  2. Koç AF, Kılıç NB, Yerdelen D, Bozdemir H. Guillain-Barré syndrome; Etiology, Clinical Findings and Plasma Exchange. Journal of Neurological Sciences (Turkish) 2005; 22:267-273
  3. Kuwabara S. Guillain-Barré Syndrome. Curr Neurol Neurosci Rep 2007; 7:57-62
  4. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double blind, sham- controlled, crossover study. Brain 1996; 119:1055-1066
  5. Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Eng J Med 1986; 314:461-465
  6. Ubogu Eroboghene E, Zaidat Osama O, Suarez José I. Acute Motor- Sensory Axonal Neuropathy Associated with Active Systemic Lupus Erythematosus and Anticardiolipin Antibodies. Journal of Clinical Rheumatology 2001; 7:326-331
  7. Yücesan C, Arslan O, Arat M, Yücemen N, Ayyildiz E, Ilhan O, Mutluer N. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: Review of 50 cases. Transfusion and Apheresis Science 2007; 36:103-107
  8. Tindall RSA, Rollins JA. Assessment of therapeutic plasmapheresis in demyelinating neurologic disorders. Ther Plasmapher 1986; 79:991- 997
  9. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders. Neurology 2011; 76:294-300
  10. Schilling S, Linker RA, König FB, Koziolek M, Bähr M, Müller GA, Paulus W, Gärtner J, Brück W, Chan A, Gold R. Plasma exchange therapy for steroid unresponsive multiple sclerosis relapses: Clinical experience with 16 patients. Nevenarzt 2006; 77:430-438
  11. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y. Therapeutic efficacy of plasma exchange in NMO-IgG positive patients with neuromyelitis optica. Mult Scler 2007; 13:128-132
  12. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993; 43:1100-1104
  13. Shariatmadar S, Noto TA. Plasma exchange in stiff-man syndrome. The Apher 2001; 5:64-67
  14. Odaka M, Yuki N, Yamada M, and et al. Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillai